← Leaderboards
Betty Kim
Mayo Clinic Jacksonville
$5,658,319
Attributed
$9,019,301
Total exposure
7
Grants
3
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2018–25$2.5M$1.9M$1.3M$625K$0
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$9,019,301 · 7
By mechanism
R01$5,889,939 · 4
UH3$1,748,902 · 1
UG3$821,727 · 1
P50$558,733 · 1
Top collaborators
- Wen Jiang6 shared
- Eduardo Reategui4 shared
Most similar at Mayo Clinic Jacksonville
Same institution · by research overlap
- Panagiotis Z Anastasiadis$6,890,926
- Lara M Mangravite$9,274,560
Others in their field
Other Emerging Leaders on “Immune”
- Bambra Strokes · Ppd Development Lp$526,656,217
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$181,310,675
- Kevin Urdahl · Seattle Children'S Hospital$84,741,409
- Ted Ross · University Of Georgia$74,507,826
- Yunda Huang · Fred Hutchinson Cancer Center$73,602,469
- Tony Moody · Duke University$66,767,417
Research focus
ImmuneAntibodiesCellsGlioblastomaMacrophageTumorTumor GrowthResponseMolecularProteinsAntigen PresentationExhibitsMembraneDesignPhagocytosisT-LymphocyteAntitumor ResponseAntitumor EffectInsightMediatingReconstitutionCancer ImmunotherapyExosomeMessenger Rna
Grant awards (18)
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$1,135,633
R01 · FY2025 · CA
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma$645,873
R01 · FY2025 · CA
Microbial-inspired immune-stimulating antibody-toxin conjugate (ATC) for cancer immunotherapy$616,715
R01 · FY2025 · CA · contact PI
Engineering mRNA encapsulated extracellular vesicles for in vivo chimeric antigen receptor macrophage therapy for glioblastoma$645,873
R01 · FY2024 · CA
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$539,426
R01 · FY2024 · CA
Engineering In Vivo Chimeric Antigen Receptor Macrophages (CARMs) using mRNA-exosomes for Cancer Immunotherapy$567,816
R01 · FY2023 · CA
Microfluidics Array Based Sorting, Isolation, and RNA Analysis in Single Extracellular V csicles$865,616
UH3 · FY2022 · TR
Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy$346,290
R01 · FY2022 · NS · contact PI
Animal Core (Core D)$193,616
P50 · FY2022 · CA · contact PI
Microfluidics Array Based Sorting, Isolation, and RNA Analysis in Single Extracellular V csicles$883,286
UH3 · FY2021 · TR
Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy$346,290
R01 · FY2021 · NS · contact PI
Animal Core (Core D)$168,970
P50 · FY2021 · CA · contact PI
Microfluidics Array Based Sorting, Isolation, and RNA Analysis in Single Extracellular V csicles$419,379
UG3 · FY2020 · TR
Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy$346,290
R01 · FY2020 · NS · contact PI
Animal Core (Core D)$196,147
P50 · FY2020 · CA · contact PI
Microfluidics Array Based Sorting, Isolation, and RNA Analysis in Single Extracellular V csicles$402,348
UG3 · FY2019 · TR
Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy$346,290
R01 · FY2019 · NS · contact PI
Therapeutic modulation of the phagocytosis axis as a novel glioblastoma immunotherapy$353,443
R01 · FY2018 · NS · contact PI